| http://www.w3.org/ns/prov#value | - It continues to expand the therapeutic potential of RNAi and SNALP and suggests the targets evaluated may have the potential to treat metabolic diseases, such as diabetes and obesity.Tekmira and its research collaborators are developing drugs based on RNA interference (RNAi), which has the potential to treat a wide range of human diseases by switching-off disease-causing genes.
|
